Table 2.
Baseline characteristics of patients in the follow‐up cohort
| Characteristic | |
|---|---|
| Sex | |
| Female, n, % | 48 (48.0%) |
| Male, n, % | 52 (52.0%) |
| Years of age, median (range) | 57 (25‐89) |
| Primary melanoma site, n, % | |
| Head | 4 (4%) |
| Trunk/back | 36 (36%) |
| Lower extremity | 41 (41%) |
| Upper extremity | 15 (15%) |
| Unknown primary | 4 (4%) |
| Breslow thickness in mm, median (range) | 2.0 (0.4‐14.0) |
| Ulceration | |
| Yes | 32 (32%) |
| No | 52 (52%) |
| Sentinel node performed | |
| Yes | 69 (69%) |
| No | 26 (26%) |
| Sentinel node positive | |
| Yes | 65 (94%) |
| No | 4 (6%) |
| Lymph node dissection | |
| CLND | 43 (43%) |
| TLND | 36 (36%) |
| Type of melanoma, n, % | |
| Superficial spreading | 64 (64%) |
| Nodular melanoma | 21 (21%) |
| Verrucous nevoid melanoma | 1 (1%) |
| Spitzoid melanoma | 1 (1%) |
| Other | 13 (13%) |
Abbreviations: CLND, completion lymph node dissection; TLND, therapeutic lymph node dissection.